Trade payables increased by $18.8 million as of June 30, 2025, compared to December 31, 2024, reflecting the increase in clinical trials spent and manufacturing.

No discounting was performed on the trade payables to the extent that the amounts did not present payment terms longer than one year at the end of each fiscal period presented.

The following tables summarize the other liabilities as of June 30, 2025 and December 31, 2024:


	June 30, 2025			December 31, 2024
	Other current liabilities	Other non-current liabilities	Total	Other current liabilities	Other non-current liabilities	Total
Employee related liabilities	6,293	—	6,293	7,294	—	7,294

Tax liabilities	625	—	625	188	—	188
Other debts	600	—	600	846	—	846
Total	7,518	—	7,518	8,328	—	8,328

The Employee related liabilities include short-term debt to employees including social welfare, tax agency obligations and bonus provision. The variance versus year end is due to bonus accruals.